Wolfram syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:58 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Wolfram syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Tirzepatide for Improving Insulin Production in Patients with Wolfram Syndrome Type 1 https://clinicaltrials.eu/trial/study-on-tirzepatide-for-improving-insulin-production-in-patients-with-wolfram-syndrome-type-1/ Wed, 29 Apr 2026 15:00:44 +0000 https://clinicaltrials.eu/trial/study-on-tirzepatide-for-improving-insulin-production-in-patients-with-wolfram-syndrome-type-1/ This clinical trial is focused on studying a rare condition known as Wolfram syndrome type 1. This syndrome is a genetic disorder that can lead to diabetes and other health issues. The study is exploring the use of a medication called tirzepatide, which is also known by its code name LY3298176. Tirzepatide is a solution for injection that is being investigated for its potential to help increase the body’s natural production of insulin in patients with Wolfram syndrome type 1.

The purpose of this study is to determine if tirzepatide can effectively improve insulin production in individuals with Wolfram syndrome type 1. Participants in the study will receive tirzepatide injections, which are administered under the skin. The study will compare different doses of tirzepatide, specifically 2.5 mg, 5 mg, and 7.5 mg, to see which is most effective. Some participants may receive a placebo for comparison. The study will last for a period of up to 12 months, during which participants will be monitored to assess their response to the treatment.

Throughout the study, participants will undergo various assessments to evaluate the effects of tirzepatide on their insulin production. The main goal is to see if there is an increase in insulin levels, which will be measured using a specific test. This research aims to provide valuable insights into whether tirzepatide can be a beneficial treatment option for managing Wolfram syndrome type 1, potentially improving the quality of life for those affected by this condition.

]]> Study on the Effects of Sodium Valproate for Hearing Preservation in Patients with Wolfram Syndrome https://clinicaltrials.eu/trial/study-on-the-effects-of-sodium-valproate-for-hearing-preservation-in-patients-with-wolfram-syndrome/ Wed, 29 Apr 2026 14:57:35 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-sodium-valproate-for-hearing-preservation-in-patients-with-wolfram-syndrome/ This clinical trial is focused on studying Wolfram syndrome, a rare genetic disorder that affects various parts of the body, including the eyes, ears, and pancreas. The study will use a medication called sodium valproate, which is commonly used to treat seizures. The purpose of the study is to see if sodium valproate can help preserve hearing in patients with Wolfram syndrome.

Participants in the study will take sodium valproate daily. The study will last for three years, during which time participants will have regular check-ups to monitor their hearing and overall health. The goal is to maintain hearing levels and prevent further hearing loss. The study will also look at other aspects of health, such as vision, balance, and sleep, to see if there are any additional benefits from the treatment.

Throughout the study, participants will undergo various tests, including hearing tests and possibly MRI scans, to assess the effects of the treatment. The safety of sodium valproate will be closely monitored, and any side effects will be recorded. This study aims to provide valuable information on whether sodium valproate can be an effective treatment for preserving hearing in individuals with Wolfram syndrome.

]]>